GeneDx to Launch Easy Order at 2026 AAP Conference to Simplify Genomic Testing for Pediatricians
GeneDx, a company focused on rare disease diagnosis and improving health through genomic data, will introduce Easy Order, a new streamlined genomic testing experience designed to make it faster and simpler for general pediatricians to order ExomeDx™ and chromosomal microarray (CMA) testing.
The new offering will be unveiled at the 2026 American Academy of Pediatrics (AAP) National Conference & Exhibition, taking place October 2-6 in San Diego. Easy Order forms part of GeneDx’s broader effort to simplify the genomic testing journey, from selecting and ordering a test to understanding results and communicating genetic findings with children and their families.
The launch comes at a time when genomic testing is becoming increasingly relevant to routine pediatric care. In 2025, the AAP updated its guidance to recommend exome or genome sequencing as a first-tier testing option for children with global developmental delay (GDD) or intellectual disability (ID). The updated recommendation represents an important shift toward incorporating genomic testing earlier in the diagnostic evaluation of children with developmental concerns.
GeneDx says its new workflow is designed to help pediatricians put that guidance into practice by reducing administrative complexity and making genomic testing more accessible to clinicians who may not routinely order genetic tests.
Making Genomic Testing More Accessible in Pediatric Care
General pediatricians are often among the first healthcare professionals to identify developmental delays, intellectual disability or other signs that may warrant further evaluation.
However, genetic testing can involve complex ordering requirements and may traditionally be associated with specialists in genetics or rare diseases. GeneDx’s Easy Order initiative is intended to reduce those barriers by providing a guided workflow through the company’s Provider Portal.
The experience reduces the amount of information that pediatricians are required to enter and is designed to help clinicians submit complete orders with greater confidence.
For pediatricians who may not regularly order genomic tests, simplifying the ordering process can be an important step toward incorporating genetic testing into routine clinical workflows.
The company’s broader approach goes beyond simply making an order form easier to complete. GeneDx is working to simplify multiple stages of the testing experience, including helping clinicians understand reports, communicate findings to families and identify appropriate next steps following a genetic diagnosis.
Linda Genen, M.D., M.P.H., Chief Medical Officer of GeneDx, said general pediatricians have an important role in recognizing developmental concerns and helping families begin the diagnostic process.
“General pediatricians are often the first to recognize developmental concerns and are uniquely positioned to help families get answers sooner,” Genen said.
She added that making genomic testing part of everyday pediatric care requires an experience designed around the needs of general pediatricians rather than only genetics specialists.
“Making genomic testing part of everyday pediatric care means designing the entire experience for the pediatrician, not just the genetics expert, so they can confidently order the right test, interpret results and talk with families about what those results mean and what comes next,” Genen said.
AAP Guidance Strengthens Role of Genomic Testing
The introduction of Easy Order follows an important change in pediatric genetic testing guidance.
In 2025, the AAP updated its recommendations concerning the genetic evaluation of children with intellectual disability and global developmental delay. The updated guidance recommends exome or genome sequencing as a first-tier testing approach, highlighting the increasing role of genomic technologies in evaluating children with unexplained developmental conditions.
The change reflects the expanding understanding of how genetic variants can contribute to developmental and neurodevelopmental conditions.
For families, obtaining a molecular diagnosis can potentially provide information about the underlying cause of a child’s condition and may help inform medical management, monitoring and referrals. A diagnosis can also help families connect with condition-specific organizations, resources and support communities.
However, translating recommendations into routine clinical practice requires more than publishing guidance. Pediatricians need practical tools, education, ordering workflows and resources that enable them to incorporate testing into existing patient-care processes.
GeneDx’s Easy Order platform is being introduced in this context, with the company seeking to make genomic testing more straightforward for clinicians who may be encountering these technologies more frequently as part of pediatric care.
Easy Order Designed for General Pediatricians
Available through the GeneDx Provider Portal, Easy Order provides a guided ordering workflow for ExomeDx™ and CMA.
The system is designed to reduce required inputs while helping pediatricians complete orders accurately.
This focus on usability is particularly relevant for general pediatric practices, where clinicians must manage a broad range of conditions and may not have specialized genetics training.
By providing a more structured process, GeneDx aims to make it easier for pediatricians to determine the appropriate testing pathway and submit complete information.
The company’s strategy is also intended to address the next stages of genomic testing. Ordering a test is only one part of the diagnostic process. Once results are returned, clinicians need to understand what the findings mean, determine whether additional evaluation is appropriate and explain the information to parents and caregivers.
GeneDx is therefore developing additional resources intended to support pediatricians throughout that process.
Provider Report Guides Aim to Simplify Results
Alongside Easy Order, GeneDx is developing Provider Report Guides designed to provide provider-friendly explanations directly within genetic testing reports.
The guides are intended to help clinicians who are not genetics specialists understand results more quickly and use the information when communicating with families.
Genetic test reports can contain technical terminology and information that may be unfamiliar to clinicians who do not regularly interpret genomic data. Providing explanations within or alongside reports could help bridge the gap between complex genomic findings and practical clinical decision-making.
GeneDx says these resources will support pediatricians as they communicate genetic findings to families and determine appropriate next steps.
The company is also developing additional educational resources intended to make genetic findings clearer and more actionable.
Together, these initiatives reflect GeneDx’s effort to address the complete testing experience rather than focusing solely on laboratory testing.
Connecting Diagnosis With Clinical Action
The importance of earlier genetic testing extends beyond obtaining a diagnostic label.
For some children, identifying a genetic cause can provide information that influences clinical management or prompts consideration of additional evaluations. A diagnosis may also help clinicians and families understand the expected course of a condition and identify relevant specialists or supportive services.
For families who have spent significant time seeking an explanation for developmental or intellectual challenges, a molecular diagnosis can also provide greater clarity about the underlying condition.
GeneDx will explore these issues during its educational programming at the AAP National Conference & Exhibition, including a session focused specifically on the importance of earlier diagnosis.
The company says the goal is to help pediatricians understand not only how to order genomic tests but also how genetic information can be incorporated into patient care.
GeneDx’s Role in the LEAD Project
GeneDx’s efforts to promote earlier genomic testing also extend beyond its own products and educational programs.
The company is serving as the implementation partner for the Leveraging Genomic Assessment of Developmental Delay (LEAD) Project, a national initiative focused on advancing earlier genomic testing for children with developmental delay and related neurodevelopmental conditions.
The initiative aligns with the broader movement toward using genomic testing earlier in the diagnostic journey.
The LEAD Project reflects the recognition that delays in reaching a genetic diagnosis can affect families, clinicians and healthcare systems. Earlier testing may provide an opportunity to identify genetic causes sooner, although the appropriate clinical application of genomic testing remains dependent on individual patient circumstances and professional medical judgment.
Through its role in the project, GeneDx is contributing to efforts to translate genomic testing recommendations into practical approaches for pediatric care.
Educational Programming at the 2026 AAP Conference
In addition to launching Easy Order, GeneDx will host educational programming at the AAP National Conference & Exhibition focused on incorporating exome and genome sequencing into pediatric practice.
One of the featured sessions is “Implementing Recommended Genetic Testing for Patients with GDD or ID: A Practical Guide for Pediatricians.”
The session is scheduled for Saturday, October 3, at 1:15 p.m. PDT at Product Theater C, booth #3020.
The program will explore the AAP recommendation concerning exome sequencing, including exome sequencing with CMA, and genome sequencing as first-line testing options for children with GDD and ID.
The session will also address how pediatricians can identify patients who may benefit from genomic testing and how genetic results can potentially contribute to more precise care.
GeneDx will discuss its clinical expertise, resources and patient support services as part of the presentation.
The company notes that the Product Theater is not designated for CME credit and is not sponsored or endorsed by the American Academy of Pediatrics.
A second program, “Diagnosis is Action: Why Earlier Answers Matter in Pediatric Care,” will take place on Saturday, October 3, at 2:00 p.m. PDT at the GeneDx booth, #1031.
The session will feature Dr. Tommy Martin, an Internal Medicine and Pediatrics physician, and Geraldine Bliss, President and Co-founder of CureSHANK.
The speakers will discuss the clinical and family perspectives associated with earlier genetic testing. Topics will include how genetic diagnoses can contribute to more personalized care and how obtaining an answer can help families connect with condition-specific resources and support.
Addressing the Diagnostic Journey From Ordering to Understanding
GeneDx’s announcement reflects a broader evolution in the role of genomic testing in pediatric medicine.
As sequencing technologies become more widely incorporated into clinical practice, the challenge increasingly involves ensuring that testing can be ordered, interpreted and communicated efficiently outside specialized genetics settings.
The updated AAP guidance provides a framework for earlier genomic testing among children with GDD or ID, but implementation depends on clinicians having practical resources that fit within routine pediatric workflows.
Easy Order is intended to address the initial stage of that process by simplifying test ordering. Provider Report Guides and educational resources address the subsequent need to understand results and communicate findings.
The company’s involvement in the LEAD Project further extends this approach into implementation efforts aimed at accelerating access to genomic testing for children with developmental delay and related neurodevelopmental conditions.
Together, these initiatives represent an effort to make genomic medicine more accessible to general pediatricians while supporting families throughout the diagnostic process.
Moving Genomic Testing Into Routine Pediatric Care
The launch of Easy Order at the 2026 AAP National Conference & Exhibition marks another step in GeneDx’s efforts to integrate genomic testing into everyday pediatric medicine.
The company’s strategy combines simplified ordering, provider-focused reporting tools, educational resources and national implementation initiatives. The objective is to help pediatricians move more efficiently from recognizing developmental concerns to considering genomic testing, understanding results and communicating findings to families.
As genomic testing becomes increasingly relevant to children with developmental delay and intellectual disability, tools that reduce administrative and interpretive barriers could play an important role in supporting broader adoption.
For GeneDx, the introduction of Easy Order is therefore positioned as part of a larger transformation in pediatric genomic care. By designing testing workflows around general pediatricians as well as genetics specialists, the company aims to help clinicians incorporate genomic information into routine practice and support families seeking answers.
The initiative will debut as pediatricians, researchers and healthcare professionals gather in San Diego for the 2026 AAP National Conference & Exhibition. With the combination of updated professional guidance, streamlined testing workflows and additional resources for interpreting and communicating results, GeneDx is seeking to help move genomic testing from a specialized service toward a more accessible component of pediatric diagnostic care.
About GeneDx
GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx® tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses.
GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,000 research publications, GeneDx is building the network that will drive the future of genomic precision medicine.